Immune profiling for cancer immunotherapy response
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies immune system changes in cancer patients receiving immunotherapy, such as checkpoint inhibitors or cell therapies. It aims to understand why some people respond better than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer and are starting or continuing immunotherapy (like Keytruda, Opdivo, Yervoy, or CAR T-cell therapy).
- You can be on any type of prior treatment, including previous immunotherapy.
- You are not pregnant, not a prisoner, and can make your own medical decisions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches immune system markers to see if they can predict which patients will respond well to immunotherapy and who might have side effects. If you have cancer and are starting immunotherapy, this trial may help guide future treatment decisions.
This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.
This trial studies how changing your immune system (with earlier treatments) affects cancer by collecting immune cells from your blood using a process called lymphapheresis. It may help researchers find better ways to monitor immune-related responses and side effects.
This is an observational study that follows adults with solid cancer who are receiving immune checkpoint inhibitor treatments. It aims to learn how these medicines are used and what outcomes may look like in everyday care.
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.